Is Fruquintinib a chemotherapy drug or a targeted drug?

Fruquintinib is a targeted drug rather than a traditional chemotherapy drug. It belongs to a class of drugs called multi-target small molecule kinase inhibitors, which work primarily by inhibiting multiple signaling pathways required for tumor cell growth.

Unlike traditional chemotherapy drugs, targeted drugs such as fruquintinib can more precisely intervene in the growth and reproduction process of cancer cells, as well as their angiogenesis in surrounding tissues. The targets of fruquintinib mainly include vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR). These receptors play a key role in tumor growth and blood supply formation.

By targeting these key molecules, fruquintinib can affect tumor cells more specifically, slowing or inhibiting their growth, thereby achieving therapeutic effects. This precise intervention can often reduce damage to healthy tissue and reduce the incidence of side effects compared with traditional chemotherapy drugs.

In general, fruquintinib, as a targeted drug, demonstrates a more advanced and precise treatment strategy, providing a more promising treatment option for cancer patients.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.